I9DN Stock Overview
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Arbutus Biopharma Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.52 |
| 52 Week High | US$2.94 |
| 52 Week Low | US$1.55 |
| Beta | 2.09 |
| 1 Month Change | 10.59% |
| 3 Month Change | 18.68% |
| 1 Year Change | 10.11% |
| 3 Year Change | -11.60% |
| 5 Year Change | 9.82% |
| Change since IPO | -39.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| I9DN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.3% | -3.1% | 1.8% |
| 1Y | 10.1% | -22.4% | 2.2% |
Price Volatility
| I9DN volatility | |
|---|---|
| I9DN Average Weekly Movement | 7.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: I9DN has not had significant price volatility in the past 3 months.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 73 | Mike McElhaugh | www.arbutusbio.com |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company’s research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients’ HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19.
Arbutus Biopharma Corporation Fundamentals Summary
| I9DN fundamental statistics | |
|---|---|
| Market cap | €462.98m |
| Earnings (TTM) | -€68.07m |
| Revenue (TTM) | €16.95m |
27.3x
P/S Ratio-6.8x
P/E RatioIs I9DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| I9DN income statement (TTM) | |
|---|---|
| Revenue | US$18.14m |
| Cost of Revenue | US$73.70m |
| Gross Profit | -US$55.56m |
| Other Expenses | US$17.29m |
| Earnings | -US$72.85m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 02, 2024
| Earnings per share (EPS) | -0.40 |
| Gross Margin | -306.26% |
| Net Profit Margin | -401.57% |
| Debt/Equity Ratio | 6.6% |
How did I9DN perform over the long term?
See historical performance and comparison